Logo

Suggestions

  • Cancer Disparities
  • Opinion
  • Conferences
  • News
  • Patient Corner
  • About
    • Contact
    • Article Submission
  • Top Headlines
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • GI Malignancies
      • Melanoma & Skin Cancer
      • GU Malignancies
      • Gynecologic Oncology
      • Hematologic Malignancies
      • Lung Cancer
  • Expert Opinion
  • Video News
  • New Approvals
  • Cancer Disparities
  • Patient Corner
  • Subscribe

Logo

breast cancer

January 26, 2023
Breast Cancer/News/Opinion

DESTINY-Breast04 Trial

By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School   “Overall, a major shift in the way we treat breast cancer has occurred in 2022, with the demonstration that patients with tumors

FDA_Approved
Breast Cancer/New Drug Applications

FDA Approves Sacituzumab Govitecan-hziy for HR+/HER2- Metastatic Breast Cancer

On February 3, 2023, the U.S. Food and Drug Administration approved sacituzumab govitecan-hziy for women 18 years or older with HR+/HER2-Metastatic Breast Cancer refractory to or relapsed after at least 2, and no more than 4, lines of prior systemic

February 7, 2023

FDA approves Elacestrant for ER-positive, HER2-negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

New Drug Applications

On January 27, 2023, the U.S. Food and Drug Administration approved elacestrant for postmenopausal, non-pregnant women and adult men with advanced or metastatic ER-positive

FDA Approves an Expanded Indication of Abemaciclib with Endocrine Therapy for Early Breast Cancer

New Drug Applications

On March 4, 2023, the U.S. Food and Drug Administration approved expanded use of adjuvant abemaciclib with endocrine therapy for adult patients with early,

Breast Cancer/Opinion

Oral SERD Elacestrant is now an option for metastatic hormone-receptor positive breast cancer: Findings from the Phase III EMERALD Trial

By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center   Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective

More
by Tiani Grosso
March 27, 2023
FDA_Approved
New Drug Applications

FDA Approves an Expanded Indication of Abemaciclib with Endocrine Therapy for Early Breast Cancer

On March 4, 2023, the U.S. Food and Drug Administration approved expanded use of adjuvant abemaciclib with endocrine therapy for adult patients with early, hormone receptor (HR)-positive, human epidermal growth factor receptor

More
by Tiani Grosso
March 7, 2023
FDA_Approved
Breast Cancer/New Drug Applications

FDA Approves Sacituzumab Govitecan-hziy for HR+/HER2- Metastatic Breast Cancer

On February 3, 2023, the U.S. Food and Drug Administration approved sacituzumab govitecan-hziy for women 18 years or older with HR+/HER2-Metastatic Breast Cancer refractory to or relapsed after at least 2, and

More
by Tiani Grosso
February 7, 2023
FDA_Approved
New Drug Applications

FDA approves Elacestrant for ER-positive, HER2-negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

On January 27, 2023, the U.S. Food and Drug Administration approved elacestrant for postmenopausal, non-pregnant women and adult men with advanced or metastatic ER-positive HER-2 negative breast cancer. Patients must have received

More
by Tiani Grosso
January 30, 2023
Breast Cancer/News/Opinion

DESTINY-Breast04 Trial

By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School   “Overall, a major shift in the way we treat breast cancer has occurred in 2022, with the demonstration that patients with tumors

More
by Tiani Grosso
January 26, 2023

your advertisement here

you may also like...

  • Oral SERD Elacestrant is now an option for metastatic hormone-receptor positive breast cancer: Findings from the Phase III EMERALD Trial
  • FDA_Approved
    FDA Approves Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma
  • Dr. Rubina Suwal of the Binaytara Foundation Cancer Center Receives ASCO International Innovation Grant
  • Dr_Luke_Fletcher
    Zuma 7 trial shows statistically significant overall survival benefit for yescarta
  • Biomarker Testing in Advanced Non-Small Cell Lung Cancer

All Categories

  • Awareness
  • Breast Cancer
  • Cancer Disparities
  • Cancer Research
  • Conference 2023
  • Conferences
  • Events
  • GI Malignancies
  • GU Malignancies
  • Hematologic Malignancies
  • Journal
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Nepal Cancer Center
  • New Drug Applications
  • News
  • Opinion
  • Patient Corner
  • Spotlights
  • Uncategorized
  • Updates
  • Video News
  • Volunteer Spotlight

Search By Keyword

2022 Summit on Cancer Health Disparities ASCO award Binaytara foundation Binaytara Foundation Cancer Center Binaytara Foundation education academy breast cancer BTF cancer cancer care cancer disparities cancer research cancer treatment cancer treatment in Nepal CME community oncologists conference Conferences continuing education Dr. Binay Shah Dr. Rubina Suwal events Expert Opinion faculty highlight FDA approved head & neck cancer surgery in Nepal healthcare equity hematological malignancies Lung cancer Nepal Nepal cancer care oncology oncology CME Opinion SCHD upcoming conferences video news Volunteer

We Transform Cancer Care

Dissect complex information on cancer and disseminate knowledge to healthcare professionals, patients, and caregivers. We want to improve patient outcomes.
Cover the latest research to promote precision oncology and patient-centered care.
Questions? Contact us -
[email protected]

Social Media

Advertisement


Footer Logo
  • Facebook
  • Twitter
  • LinkedIn
  • Email

© 2023 - All Rights Reserved. Binaytara Foundation

  • About
  • Submit an Article
  • Subscribe for updates
  • Editorial Board
  • Privacy Policy
  • Contact
  • Home
  • Top Headlines
    • Awareness
    • Video News
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • Melanoma & Skin Cancer
      • GI Malignancies
      • Lung Cancer
      • Hematologic Malignancies
      • Gynecologic Oncology
      • GU Malignancies
  • New in Cancer Care
  • Conferences
    • Hemotology & Oncology Conference Calendar
    • Conference Calendar
    • Conference Coverage
  • New Approvals
  • Contact us
  • Submit an article